So far, virtually all approved therapeutic antibody preparations for clinical practice including for cancer treatment are in IgG backbone,26 while recently the importance of implementing dimeric IgA‐based therapeutic antibodies has been underscored.27, 28. The gene discussed is CD79A; the disease is cancer.